GLP-1RA induces weight loss in adults with overweight or obesity - PACE-CME

GLPRA induces weight loss in adults with overweight or obesity

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
AHA 2024
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
- Subodh Verma, MD, PhD
Tirzepatide reduces HF events in patients with HFpEF and obesity
Tirzepatide reduces HF events in patients with HFpEF and obesity
AHA 2024
Tirzepatide reduces HF events in patients with HFpEF and obesity
- Milton Packer, MD
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
AHA 2023
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
- Michael Lincoff, MD
Improvement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD
Improvement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD
AHA 2023
Improvement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD
- Ania Jastreboff, MD, PhD